Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Cognitive Impairment Associated With Schizophrenia (CIAS) - Overview
Cognitive Impairment Associated With Schizophrenia (CIAS) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Cognitive Impairment Associated With Schizophrenia (CIAS) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Cognitive Impairment Associated With Schizophrenia (CIAS) - Companies Involved in Therapeutics Development
Accure Therapeutics SL
Anvyl LLC
Astellas Pharma Inc
AstraZeneca Plc
Autifony Therapeutics Ltd
Biogen Inc
Boehringer Ingelheim Intertiol GmbH
Bristol-Myers Squibb Co
Cadent Therapeutics Inc
Coronis NeuroSciences Ltd
F. Hoffmann-La Roche Ltd
H. Lundbeck AS
Neurocrine Biosciences Inc
Pfizer Inc
SK Biopharmaceuticals Co Ltd
Spherium Biomed SL
Suven Life Sciences Ltd
Vanda Pharmaceuticals Inc
Cognitive Impairment Associated With Schizophrenia (CIAS) - Drug Profiles
ACT-02 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ASP-5736 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AUT-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AUT-6 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AUT-9 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AVL-3288 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
basmisanil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BI-425809 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BIIB-104 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMS-955829 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CAD-8688 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CAD-9303 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CP-102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LuAF-88434 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PF-03463275 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cognitive Impairment Associated With Schizophrenia (CIAS) - Dormant Projects
Cognitive Impairment Associated With Schizophrenia (CIAS) - Discontinued Products
Cognitive Impairment Associated With Schizophrenia (CIAS) - Product Development Milestones
Featured News & Press Releases
Feb 01, 2015: ASCIL Biopharm cooperates in a Project awarded with a “RETOS-Colaboraci?n” grant
Jan 27, 2015: Spark, a new public-private project created to develop a drug to fight the cognitive impairment associated with schizophrenia
Apr 17, 2013: SK Biopharma Announces FDA’s Authorization Of IND For SKL15508 For Treatment Of Cognitive Impairment Associated With Schizophrenia
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development for Cognitive Impairment Associated With Schizophrenia (CIAS), H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products by Top 10 Targets, H2 2020
Number of Products by Stage and Top 10 Targets, H2 2020
Number of Products by Top 10 Mechanism of Actions, H2 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020


List of Tables


Number of Products under Development for Cognitive Impairment Associated With Schizophrenia (CIAS), H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020 (Contd..1), H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Accure Therapeutics SL, H2 2020
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Anvyl LLC, H2 2020
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Astellas Pharma Inc, H2 2020
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by AstraZeneca Plc, H2 2020
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Autifony Therapeutics Ltd, H2 2020
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Biogen Inc, H2 2020
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Boehringer Ingelheim International GmbH, H2 2020
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Bristol-Myers Squibb Co, H2 2020
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Cadent Therapeutics Inc, H2 2020
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Coronis NeuroSciences Ltd, H2 2020
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by F. Hoffmann-La Roche Ltd, H2 2020
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by H. Lundbeck AS, H2 2020
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Neurocrine Biosciences Inc, H2 2020
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Pfizer Inc, H2 2020
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by SK Biopharmaceuticals Co Ltd, H2 2020
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Spherium Biomed SL, H2 2020
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Suven Life Sciences Ltd, H2 2020
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Vanda Pharmaceuticals Inc, H2 2020
Cognitive Impairment Associated With Schizophrenia (CIAS) - Dormant Projects, H2 2020
Cognitive Impairment Associated With Schizophrenia (CIAS) - Dormant Projects, H2 2020 (Contd..1), H2 2020
Cognitive Impairment Associated With Schizophrenia (CIAS) - Dormant Projects, H2 2020 (Contd..2), H2 2020
Cognitive Impairment Associated With Schizophrenia (CIAS) - Discontinued Products, H2 2020